Analysts predict that Zosano Pharma Corp (NASDAQ:ZSAN) will post ($0.24) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Zosano Pharma’s earnings. Zosano Pharma posted earnings per share of ($0.46) during the same quarter last year, which indicates a positive year-over-year growth rate of 47.8%. The firm is expected to announce its next earnings results on Wednesday, March 7th.
According to Zacks, analysts expect that Zosano Pharma will report full year earnings of ($0.90) per share for the current financial year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.90) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Zosano Pharma.
Zosano Pharma (NASDAQ:ZSAN) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05).
Separately, ValuEngine upgraded shares of Zosano Pharma from a “strong sell” rating to a “sell” rating in a research note on Sunday, December 31st.
In related news, Director Kenneth Greathouse bought 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was acquired at an average cost of $0.62 per share, for a total transaction of $31,000.00. Following the purchase, the director now owns 35,000 shares in the company, valued at $21,700. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last quarter, insiders have acquired 200,000 shares of company stock valued at $123,450. Company insiders own 2.95% of the company’s stock.
A hedge fund recently raised its stake in Zosano Pharma stock. Northern Trust Corp grew its holdings in shares of Zosano Pharma Corp (NASDAQ:ZSAN) by 591.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 79,234 shares of the biotechnology company’s stock after acquiring an additional 67,774 shares during the period. Northern Trust Corp owned about 0.20% of Zosano Pharma worth $112,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 19.41% of the stock is currently owned by institutional investors.
Shares of Zosano Pharma (ZSAN) traded down $0.04 on Thursday, reaching $0.45. 1,258,334 shares of the company’s stock were exchanged, compared to its average volume of 473,924. The stock has a market cap of $17.76, a price-to-earnings ratio of -0.38 and a beta of 2.50. Zosano Pharma has a 1-year low of $0.40 and a 1-year high of $3.54.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/13/0-24-eps-expected-for-zosano-pharma-corp-zsan-this-quarter.html.
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Get a free copy of the Zacks research report on Zosano Pharma (ZSAN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.